Skip to main content
. 2021 Jun 7;13(1):1930636. doi: 10.1080/19420862.2021.1930636

Table 4.

Germline usage and somatic hypermutation rate (SHM) of antibodies

Antibody V-H allele J-H allele CDR3 length (aa) SHM (%)
JMB2002 Vκ IGKV1-33*01 IGKJ4*01 9 4.7
JMB2002 VH IGHV1-69*18 IGHJ5*02 16 0.0
CB6 Vκ IGKV1-39*01 IGKJ2*01 11 1.8
CB6 VH IGHV3-66*01 IGHJ4*01 13 3.4
Imdevimab (REGN10987) Vλ IGLV2-14*03 IGLJ3*02 10 4.5
Imdevimab (REGN10987) VH IGHV3-30*01 IGHJ4*01 13 2.5